Guest guest Posted April 19, 2011 Report Share Posted April 19, 2011 , I usually love your posts, however, Tagamet is not something to take lightly - check this out from Drugs.com: Adverse effects reported in patients taking Tagamet are described below by body system. Incidence figures of 1 in 100 and greater are generally derived from controlled clinical studies. Gastrointestinal Diarrhea (usually mild) has been reported in approximately 1 in 100 patients. CNS Headaches, ranging from mild to severe, have been reported in 3.5% of 924 patients taking 1600 mg/day, 2.1% of 2,225 patients taking 800 mg/day and 2.3% of 1,897 patients taking placebo. Dizziness and somnolence (usually mild) have been reported in approximately 1 in 100 patients on either 1600 mg/day or 800 mg/day. Reversible confusional states, e.g., mental confusion, agitation, psychosis, depression, anxiety, hallucinations, disorientation, have been reported predominantly, but not exclusively, in severely ill patients. They have usually developed within 2 to 3 days of initiation of Tagamet therapy and have cleared within 3 to 4 days of discontinuation of the drug. Endocrine Gynecomastia has been reported in patients treated for 1 month or longer. In patients being treated for pathological hypersecretory states, this occurred in about 4% of cases while in all others the incidence was 0.3% to 1% in various studies. No evidence of induced endocrine dysfunction was found, and the condition remained unchanged or returned toward normal with continuing Tagamet (cimetidine) treatment. Reversible impotence has been reported in patients with pathological hypersecretory disorders, e.g., Zollinger-Ellison Syndrome, receiving Tagamet, particularly in high doses, for at least 12 months (range 12 to 79 months, mean 38 months). However, in large-scale surveillance studies at regular dosage, the incidence has not exceeded that commonly reported in the general population. Hematologic Decreased white blood cell counts in Tagamet-treated patients (approximately 1 per 100,000 patients), including agranulocytosis (approximately 3 per million patients), have been reported, including a few reports of recurrence on rechallenge. Most of these reports were in patients who had serious concomitant illnesses and received drugs and/or treatment known to produce neutropenia. Thrombocytopenia (approximately 3 per million patients) and, very rarely, cases of pancytopenia or aplastic anemia have also been reported. As with some other H2-receptor antagonists, there have been extremely rare reports of immune hemolytic anemia. Hepatobiliary Dose-related increases in serum transaminase have been reported. In most cases they did not progress with continued therapy and returned to normal at the end of therapy. There have been rare reports of cholestatic or mixed cholestatic-hepatocellular effects. These were usually reversible. Because of the predominance of cholestatic features, severe parenchymal injury is considered highly unlikely. However, as in the occasional liver injury with other H2-receptor antagonists, in exceedingly rare circumstances fatal outcomes have been reported. There has been reported a single case of biopsy-proven periportal hepatic fibrosis in a patient receiving Tagamet. Rare cases of pancreatitis, which cleared on withdrawal of the drug, have been reported. Hypersensitivity Rare cases of fever and allergic reactions including anaphylaxis and hypersensitivity vasculitis, which cleared on withdrawal of the drug, have been reported. Renal Small, possibly dose-related increases in plasma creatinine, presumably due to competition for renal tubular secretion, are not uncommon and do not signify deteriorating renal function. Rare cases of interstitial nephritis and urinary retention, which cleared on withdrawal of the drug, have been reported. Cardiovascular Rare cases of bradycardia, tachycardia and A-V heart block have been reported with H2-receptor antagonists. Musculoskeletal There have been rare reports of reversible arthralgia and myalgia; exacerbation of joint symptoms in patients with preexisting arthritis has also been reported. Such symptoms have usually been alleviated by a reduction in Tagamet (cimetidine) dosage. Rare cases of polymyositis have been reported, but no causal relationship has been established. Integumental Mild rash and, very rarely, cases of severe generalized skin reactions including s- syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis and generalized exfoliative erythroderma have been reported with H2-receptor antagonists. Reversible alopecia has been reported very rarely. Immune Function There have been extremely rare reports of strongyloidiasis hyperinfection in immunocompromised patients. DRUG INTERACTIONS Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly. Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects. However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur®, Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older. Data beyond 10 days are not available. (Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.) Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels. Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole). If these products are needed, they should be given at least 2 hours before cimetidine administration. Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet. Last reviewed on RxList: 1/12/2005 http://www.rxlist.com/tagamet-drug.htm Nola Chris Re: [low dose naltrexone] Thyroid Margaret, this is not medical advice, but I suggest you may try tagamet afore trying stablon. I have used stablon off and on for ten years, great to boost energy and socializing. Very safe, no sides to speak of, can start and stop at anytime. Tagamet, an over the counter anti-acid slows the metabolism of estrogen, and the end result would be more estrogen in your body. I am male, and it gave me erectile dysfunction because of the increase of estrogen. It does cause gyno, male breast development in males. Tag will stop digestion, as it neutralizes the hydrochloric acid in our stomach, so it must be taken two to three hours after a meal. An ideal situation would be to take some Betaine HCL with your meal, then tag three hours later. I was taking two tabs daily, but you would decide your dosage by how you may feel. Ninety percent of our serotonin, the feel good neuro-transmitter is made in the small intestines, although medics tell us, that serotonin does not reach the brain. Serotonin increase is what most anti depressants attempt to do, stablon encourages serotonin to work mroe effeciently.. It does make some sense, if the small intestines are producing sufficient amounts of serotonin, the body can send along to the brain, more pre-cursors, 5HTP, to the brain to make serotonin. No one can argue with that. So proper digestion is important to resolve depression, 5HTP is the precursor to serotonin, so it must be digested and metabolized and then hauled to our brain. and we smile. So you might consider taking Betaine HCL, digestive enzymes, tagamet. I think a great protocol for post meno females, there should be no sides. But just my personal opinion. stay vertical, david lubbock tx. On 4/19/11, margaret mcguinness <mrgrtmcguinness@...> wrote: > Hi all > > I have been taking LDN since October 09 and am a lot better since starting > it.I > was in a bad way and although I have had underactive thyroid for 20years it > is > the past 4 that I suffered after giving up smoking 60 a day.I have seen an > endicrinologist on the NHS (no good) but in the end it was my own research > which > helped.I found LDN looking for help for my best friend who was diagnosed 3 > yeasr > ago with MS age 49. > > I now find that I am suffering from low mood.I have not had this feeling > since > my son was born and he will be 28 next week.I suffered post natal depression > then.I hate the thought of anti depressents and think it must be my hormones > (or > lack of them) causing this dark feeling.I hate the thought of HRT and did > try > the "natural" progesterone cream which was onlly slightly helpful.I take > thyroxine 125mcg per day and have regular blood tests.I take 3.5 LDN per > night.I > also suffer from Lican Planus which was discovered in OCt 09 which is why I > started the LDN. > > I am wondering if I should buy some Tineptine (stablon) as I have heard they > are > different to usual anti depressents???? Can anyone offer any advise and > would it > be ok to take with LDN and thyroxine.LDN from my GP "off Label" > > Sorry for being so long > Margaret Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 20, 2011 Report Share Posted April 20, 2011 Hi Nola, That’s very extensive, thanks for sharing. I also had a concern re Tagamet as it was being posted a lot on another group. I shared this:- Low stomach acid also puts you at an increased risk of food poisoning since you are missing your primary defense against bacterial organisms. It has been shown that the drugs that inhibit stomach acid, such as Prilosec and Tagamet, can cause an increase in stomach bacteria and inflammation. Here's the link http://www.charlespoliquin.com/ArticlesMultimedia/Articles/Article/27/Maximize_Your_Progress_with_Hydrochloric_Acid.aspxJayne Crocker www.LDNNow.comImportant! Please sign our LDN petition to the European Parliament by clicking heretel: +44 (0) 7877 492 669Dr Steele MBE, talking about LDNLDNNow are a political/pressure group of individuals dedicated to getting Low Dose Naltrexone (LDN) accepted into modern medicine and trialled for the myriad of uses it shows benefit for. . From: low dose naltrexone [mailto:low dose naltrexone ] On Behalf Of smalk50@...Sent: 19 April 2011 19:29dhallgar@...; mrgrtmcguinness@...; low dose naltrexone Subject: Re: [low dose naltrexone] Thyroid - re: Tagamet , I usually love your posts, however, Tagamet is not something to take lightly - check this out from Drugs.com: Adverse effects reported in patients taking Tagamet are described below by body system. Incidence figures of 1 in 100 and greater are generally derived from controlled clinical studies. Gastrointestinal Diarrhea (usually mild) has been reported in approximately 1 in 100 patients. CNS Headaches, ranging from mild to severe, have been reported in 3.5% of 924 patients taking 1600 mg/day, 2.1% of 2,225 patients taking 800 mg/day and 2.3% of 1,897 patients taking placebo. Dizziness and somnolence (usually mild) have been reported in approximately 1 in 100 patients on either 1600 mg/day or 800 mg/day. Reversible confusional states, e.g., mental confusion, agitation, psychosis, depression, anxiety, hallucinations, disorientation, have been reported predominantly, but not exclusively, in severely ill patients. They have usually developed within 2 to 3 days of initiation of Tagamet therapy and have cleared within 3 to 4 days of discontinuation of the drug. Endocrine Gynecomastia has been reported in patients treated for 1 month or longer. In patients being treated for pathological hypersecretory states, this occurred in about 4% of cases while in all others the incidence was 0.3% to 1% in various studies. No evidence of induced endocrine dysfunction was found, and the condition remained unchanged or returned toward normal with continuing Tagamet (cimetidine) treatment.Reversible impotence has been reported in patients with pathological hypersecretory disorders, e.g., Zollinger-Ellison Syndrome, receiving Tagamet, particularly in high doses, for at least 12 months (range 12 to 79 months, mean 38 months). However, in large-scale surveillance studies at regular dosage, the incidence has not exceeded that commonly reported in the general population. Hematologic Decreased white blood cell counts in Tagamet-treated patients (approximately 1 per 100,000 patients), including agranulocytosis (approximately 3 per million patients), have been reported, including a few reports of recurrence on rechallenge. Most of these reports were in patients who had serious concomitant illnesses and received drugs and/or treatment known to produce neutropenia. Thrombocytopenia (approximately 3 per million patients) and, very rarely, cases of pancytopenia or aplastic anemia have also been reported. As with some other H2-receptor antagonists, there have been extremely rare reports of immune hemolytic anemia. Hepatobiliary Dose-related increases in serum transaminase have been reported. In most cases they did not progress with continued therapy and returned to normal at the end of therapy. There have been rare reports of cholestatic or mixed cholestatic-hepatocellular effects. These were usually reversible. Because of the predominance of cholestatic features, severe parenchymal injury is considered highly unlikely. However, as in the occasional liver injury with other H2-receptor antagonists, in exceedingly rare circumstances fatal outcomes have been reported. There has been reported a single case of biopsy-proven periportal hepatic fibrosis in a patient receiving Tagamet. Rare cases of pancreatitis, which cleared on withdrawal of the drug, have been reported. Hypersensitivity Rare cases of fever and allergic reactions including anaphylaxis and hypersensitivity vasculitis, which cleared on withdrawal of the drug, have been reported. Renal Small, possibly dose-related increases in plasma creatinine, presumably due to competition for renal tubular secretion, are not uncommon and do not signify deteriorating renal function. Rare cases of interstitial nephritis and urinary retention, which cleared on withdrawal of the drug, have been reported. Cardiovascular Rare cases of bradycardia, tachycardia and A-V heart block have been reported with H2-receptor antagonists. Musculoskeletal There have been rare reports of reversible arthralgia and myalgia; exacerbation of joint symptoms in patients with preexisting arthritis has also been reported. Such symptoms have usually been alleviated by a reduction in Tagamet (cimetidine) dosage. Rare cases of polymyositis have been reported, but no causal relationship has been established. Integumental Mild rash and, very rarely, cases of severe generalized skin reactions including s- syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis andgeneralized exfoliative erythroderma have been reported with H2-receptor antagonists. Reversible alopecia has been reported very rarely. Immune FunctionThere have been extremely rare reports of strongyloidiasis hyperinfection in immunocompromised patients.DRUG INTERACTIONSTagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly. Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects. However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur®, Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older. Data beyond 10 days are not available. (Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole). If these products are needed, they should be given at least 2 hours before cimetidine administration. Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet.Last reviewed on RxList: 1/12/2005 http://www.rxlist.com/tagamet-drug.htm Nola Chris_,___ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 20, 2011 Report Share Posted April 20, 2011 I see your point, JC, I was not aware of these side affects, david lubbock tx. On 4/19/11, smalk50@... <smalk50@...> wrote: > , > > I usually love your posts, however, Tagamet is not something to take lightly > - check this out from Drugs.com: > > > Adverse effects reported in patients taking Tagamet are described below by > body system. Incidence figures of 1 in 100 and greater are generally derived > from controlled clinical studies. > > Gastrointestinal > > Diarrhea (usually mild) has been reported in approximately 1 in 100 > patients. > > CNS > > Headaches, ranging from mild to severe, have been reported in 3.5% of 924 > patients taking 1600 mg/day, 2.1% of 2,225 patients taking 800 mg/day and > 2.3% of 1,897 patients taking placebo. Dizziness and somnolence (usually > mild) have been reported in approximately 1 in 100 patients on either 1600 > mg/day or 800 mg/day. > > Reversible confusional states, e.g., mental confusion, agitation, psychosis, > depression, anxiety, hallucinations, disorientation, have been reported > predominantly, but not exclusively, in severely ill patients. They have > usually developed within 2 to 3 days of initiation of Tagamet therapy and > have cleared within 3 to 4 days of discontinuation of the drug. > > Endocrine > > Gynecomastia has been reported in patients treated for 1 month or longer. In > patients being treated for pathological hypersecretory states, this occurred > in about 4% of cases while in all others the incidence was 0.3% to 1% in > various studies. No evidence of induced endocrine dysfunction was found, and > the condition remained unchanged or returned toward normal with continuing > Tagamet (cimetidine) treatment. > Reversible impotence has been reported in patients with pathological > hypersecretory disorders, e.g., Zollinger-Ellison Syndrome, receiving > Tagamet, particularly in high doses, for at least 12 months (range 12 to 79 > months, mean 38 months). However, in large-scale surveillance studies at > regular dosage, the incidence has not exceeded that commonly reported in the > general population. > > Hematologic > > Decreased white blood cell counts in Tagamet-treated patients (approximately > 1 per 100,000 patients), including agranulocytosis (approximately 3 per > million patients), have been reported, including a few reports of recurrence > on rechallenge. Most of these reports were in patients who had serious > concomitant illnesses and received drugs and/or treatment known to produce > neutropenia. Thrombocytopenia (approximately 3 per million patients) and, > very rarely, cases of pancytopenia or aplastic anemia have also been > reported. As with some other H2-receptor antagonists, there have been > extremely rare reports of immune hemolytic anemia. > > Hepatobiliary > > Dose-related increases in serum transaminase have been reported. In most > cases they did not progress with continued therapy and returned to normal at > the end of therapy. There have been rare reports of cholestatic or mixed > cholestatic-hepatocellular effects. These were usually reversible. Because > of the predominance of cholestatic features, severe parenchymal injury is > considered highly unlikely. However, as in the occasional liver injury with > other H2-receptor antagonists, in exceedingly rare circumstances fatal > outcomes have been reported. > > There has been reported a single case of biopsy-proven periportal hepatic > fibrosis in a patient receiving Tagamet. > > Rare cases of pancreatitis, which cleared on withdrawal of the drug, have > been reported. > > Hypersensitivity > > Rare cases of fever and allergic reactions including anaphylaxis and > hypersensitivity vasculitis, which cleared on withdrawal of the drug, have > been reported. > > Renal > > Small, possibly dose-related increases in plasma creatinine, presumably due > to competition for renal tubular secretion, are not uncommon and do not > signify deteriorating renal function. Rare cases of interstitial nephritis > and urinary retention, which cleared on withdrawal of the drug, have been > reported. > > Cardiovascular > > Rare cases of bradycardia, tachycardia and A-V heart block have been > reported with H2-receptor antagonists. > > Musculoskeletal > > There have been rare reports of reversible arthralgia and myalgia; > exacerbation of joint symptoms in patients with preexisting arthritis has > also been reported. Such symptoms have usually been alleviated by a > reduction in Tagamet (cimetidine) dosage. Rare cases of polymyositis have > been reported, but no causal relationship has been established. > > Integumental > > Mild rash and, very rarely, cases of severe generalized skin reactions > including s- syndrome, epidermal necrolysis, erythema > multiforme, exfoliative dermatitis and > generalized exfoliative erythroderma have been reported with H2-receptor > antagonists. Reversible alopecia has been reported very rarely. > > > Immune Function > There have been extremely rare reports of strongyloidiasis hyperinfection in > immunocompromised patients. > > > DRUG INTERACTIONSTagamet, apparently through an effect on certain microsomal > enzyme systems, has been reported to reduce the hepatic metabolism of > warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, > chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, > theophylline and metronidazole, thereby delaying elimination and increasing > blood levels of these drugs. > > Clinically significant effects have been reported with the warfarin > anticoagulants; therefore, close monitoring of prothrombin time is > recommended, and adjustment of the anticoagulant dose may be necessary when > Tagamet is administered concomitantly. Interaction with phenytoin, lidocaine > and theophylline has also been reported to produce adverse clinical effects. > > However, a crossover study in healthy subjects receiving either Tagamet 300 > mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of > theophylline (Theo-Dur®, Key Pharmaceuticals, Inc.) demonstrated less > alteration in steady-state theophylline peak serum levels with the 800 mg > h.s. regimen, particularly in subjects aged 54 years and older. Data beyond > 10 days are not available. (Note: All patients receiving theophylline should > be monitored appropriately, regardless of concomitant drug therapy.) > Dosage of the drugs mentioned above and other similarly metabolized drugs, > particularly those of low therapeutic ratio or in patients with renal and/or > hepatic impairment, may require adjustment when starting or stopping > concomitantly administered Tagamet to maintain optimum therapeutic blood > levels. > Alteration of pH may affect absorption of certain drugs (e.g., > ketoconazole). If these products are needed, they should be given at least 2 > hours before cimetidine administration. > > Additional clinical experience may reveal other drugs affected by the > concomitant administration of Tagamet. > Last reviewed on RxList: 1/12/2005 > > > > > > http://www.rxlist.com/tagamet-drug.htm > > > > Nola Chris > > Re: [low dose naltrexone] Thyroid > > Margaret, this is not medical advice, but I suggest you may try > tagamet afore trying stablon. > I have used stablon off and on for ten years, great to boost energy > and socializing. Very safe, no sides to speak of, can start and stop > at anytime. > Tagamet, an over the counter anti-acid slows the metabolism of > estrogen, and the end result would be more estrogen in your body. I am > male, and it gave me erectile dysfunction because of the increase of > estrogen. It does cause gyno, male breast development in males. > Tag will stop digestion, as it neutralizes the hydrochloric acid in > our stomach, so it must be taken two to three hours after a meal. An > ideal situation would be to take some Betaine HCL with your meal, then > tag three hours later. > I was taking two tabs daily, but you would decide your dosage by how > you may feel. > Ninety percent of our serotonin, the feel good neuro-transmitter is > made in the small intestines, although medics tell us, that serotonin > does not reach the brain. Serotonin increase is what most anti > depressants attempt to do, stablon encourages serotonin to work mroe > effeciently.. It does make some sense, if the small intestines are > producing sufficient amounts of serotonin, the body can send along to > the brain, more pre-cursors, 5HTP, to the brain to make serotonin. No > one can argue with that. > So proper digestion is important to resolve depression, 5HTP is the > precursor to serotonin, so it must be digested and metabolized and > then hauled to our brain. and we smile. > So you might consider taking Betaine HCL, digestive enzymes, tagamet. > I think a great protocol for post meno females, there should be no > sides. But just my personal opinion. stay vertical, > david lubbock tx. > > On 4/19/11, margaret mcguinness & lt;mrgrtmcguinness@... & gt; wrote: > & gt; Hi all > & gt; > & gt; I have been taking LDN since October 09 and am a lot better since > starting > & gt; it.I > & gt; was in a bad way and although I have had underactive thyroid for > 20years it > & gt; is > & gt; the past 4 that I suffered after giving up smoking 60 a day.I have seen > an > & gt; endicrinologist on the NHS (no good) but in the end it was my own > research > & gt; which > & gt; helped.I found LDN looking for help for my best friend who was > diagnosed 3 > & gt; yeasr > & gt; ago with MS age 49. > & gt; > & gt; I now find that I am suffering from low mood.I have not had this > feeling > & gt; since > & gt; my son was born and he will be 28 next week.I suffered post natal > depression > & gt; then.I hate the thought of anti depressents and think it must be my > hormones > & gt; (or > & gt; lack of them) causing this dark feeling.I hate the thought of HRT and > did > & gt; try > & gt; the " natural " progesterone cream which was onlly slightly helpful.I > take > & gt; thyroxine 125mcg per day and have regular blood tests.I take 3.5 LDN > per > & gt; night.I > & gt; also suffer from Lican Planus which was discovered in OCt 09 which is > why I > & gt; started the LDN. > & gt; > & gt; I am wondering if I should buy some Tineptine (stablon) as I have heard > they > & gt; are > & gt; different to usual anti depressents???? Can anyone offer any advise and > & gt; would it > & gt; be ok to take with LDN and thyroxine.LDN from my GP " off Label " > & gt; > & gt; Sorry for being so long > & gt; Margaret > > > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.